4D Molecular Therapeutics strengthened the Company’s senior management team with the appointments of Dhaval Desai, PharmD, as Chief Development Officer, Christopher Simms as Chief Commercial Officer and Carlos Quezada-Ruiz, M.D., FASRS, as SVP, Therapeutic Area Head, Ophthalmology. Desai most recently SVP & Chief Development Officer at Iveric Bio where he led development and approval of IZERVAY. Simms most recently SVP & Chief Commercial Officer at Iveric Bio where he led commercial strategy and execution for the launch of IZERVAY. Quezada-Ruiz most recently Group Medical Director, Ophthalmology at Genentech where he led clinical development and approval of VABYSMO and SUSVIMO
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FDMT:
- 4DMT Advances Leadership in Large Market Ophthalmology with Senior Management Hires and Formation of Ophthalmology Advisory Board
- 4D Molecular Therapeutics to Present PRISM Trial Interim Data
- Chardan maintains odds of success assumptions for 4D Molecular after data
- RBC thinks 4D-150 continues to look ‘best-in-class’ despite ‘safety blip’
- 4D Molecular price target lowered to $40 from $63 at BMO Capital